United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company hungary - 30's (10's blister x 3) - tablet - combination - cardiovascular system-nitrates , calcium-channel blockers, cardiovascular system-beta-adrenoceptor blockers

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company hungary - 30's (10's blister x 3) - tablet - combination - cardiovascular system-nitrates , calcium-channel blockers, cardiovascular system-beta-adrenoceptor blockers

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

unicare medical trading l.l.c hungary - 30's (10's blister x 3) - capsule - 10mg/ 10mg /capsule - cardiovascular system-lipid-regulators

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

unicare medical trading l.l.c hungary - 30's (10's blister x 3) - capsule - 20mg/ 10mg /capsule - cardiovascular system-lipid-regulators

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - ethofumesate - ethofumesate 500 g/litre - herbicide

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - pyrimethanil - suspension concentrate - pyrimethanil 400 g/litre - fungicide - fungicide

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; disodium edetate; purified talc - this product accepted for registration as 'currently supplied' at the time of commencement of the act. variation to pregnancy statement in product information were approved as specified in the letter of 13 august 1992 from dr bijoy varma. indicated for the treatment of drug resistant, moderate to severe, hypertension. this drug is not a first line antihypertensive drug and is better used in combination with other therapy such as a sympatholytic agent and a diuretic. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

Australia - English - Department of Health (Therapeutic Goods Administration)

jmac (wa) pty ltd trading as pharmaust manufacturing - calamine, quantity: 50 mg/g - lotion - excipient ingredients: arachis oil; quaternium-15; calcium hydroxide; wool fat; purified water; oleic acid - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) for the temporary relief of insect bites and stings

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vancomycin hydrochloride, quantity: 128 mg (equivalent: vancomycin, qty 125 mg) - capsule - excipient ingredients: iron oxide red; gelatin; indigo carmine; titanium dioxide; macrogol 6000; iron oxide yellow - this product accepted for registration as 'currently supplied' at the time of commencement of the act. revisions of product information was approved as specified in the letter of 13 august 1992 from dr alex proudfoot advising of approval for registration of the goods. indicated for the treatment of staphylococcal enterocolitis and antibiotic - associated pseudomembranous colitis produced by c. difficile.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vancomycin hydrochloride, quantity: 256 mg (equivalent: vancomycin, qty 250 mg) - capsule - excipient ingredients: iron oxide black; titanium dioxide; indigo carmine; iron oxide red; gelatin; macrogol 6000 - this product accepted for registration as 'currently supplied' at the time of commencement of the act. revision of product information was approved as specified in the letter of 13 august 1992 from dr alex proudfoot advising of approval for registration of the goods. indicated for staphylococcal enterocolitis and antibiotic - associated pseudomembranous colitis produced by c. difficile.